Note to readers: EL PAÍS openly offers essential information on the coronavirus during the crisis.
If you want to support our journalism,
subscribe here
.
The US pharmaceutical company Pfizer and the German company BioNTech have announced that this Friday they are going to request the US drug agency, the FDA, for emergency approval permission for their vaccine. On Thursday the company released the results of the tests that have statistical validity, since the clinical trial of about 44,000 patients has already reached the goal for this: that 170 infections were registered. Of these, 162 infections have occurred in the group of people who received a placebo (water with salts) and eight in which they received the two doses of the vaccine, which is 95% effective. The President of the Government, Pedro Sánchez, has explained that on Tuesday the Council of Ministers will approve the vaccination plan against the coronavirus. "Spain will be the first European country with Germany to have a vaccination plan," he indicated, adding that he plans to immunize "a very substantial part of the population" in the first half of 2021. The Community of Madrid has announced the Perimeter closure of the region between December 4 and 13, during the Constitution Bridge. In Europe, the EU prepares more than 8.4 billion euros (about 10 billion dollars) to buy lots of the vaccine from Pfizer and BioNtech or that of the company CureVac. The 27 have agreed to pay 15.5 euros for each dose of the Pfizer vaccine and about 10 euros for each dose of a first batch ordered from the biopharmaceutical company CureVac.
